Welcome to AD/PD™ Education on UNLOK!
Discover our education portal designed for healthcare professionals specializing in Neurology. Sign up today to gain exclusive access to valuable insights and resources and to stay updated through our live events.
This platform is your gateway to a treasure trove of valuable information and resources, meticulously curated to empower healthcare professionals specializing in neurology.
Register in 3 clicks today to start learning!
WHAT IS NEW FROM AD/PD™ Education on UNLOK?
AD/PD™ 2026 Evidence to Asian Practice: AD Roundtable Session - TNS Members
TNS Members: Watch this on-demand session for expert insights on applying global Alzheimer’s research to clinical practice in Asia.
AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases
Did you know AD/PD™ offers a podcast to help you revisit key conference insights? Also, an exclusive new podcast season on early Alzheimer’s detection and biomarkers is in the making. Stay tuned!
Roundtable Session: AD/PD™ 2026 Evidence to Asian Practice: AD Session
Watch this on-demand session, where leading experts translate key global Alzheimer’s research into practical, regionally relevant insights for clinical implementation across Asia.
EVENT RECORDINGS
The Necessity for Robust Assays in Early Alzheimer’s Diagnostics
Catch up on this expert-led AD/PD™ Research Spotlight exploring the rapidly evolving role of blood-based biomarkers in the early detection of Alzheimer’s disease.
Phase I trial of hES cell-derived dopaminergic neurons for PD
Discussed the scientific rationale for restoring the nigrostriatal pathway, review key findings from ongoing and completed studies, and address the methodological and translational challenges of regenerative medicine.
Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
Watch this engaging and insightful session with Prof. Michelle Mielke of Wake Forest University and Prof. Henrik Zetterberg of the University of Gothenburg, as they explore the role of tau and neurodegeneration biomarkers in Alzheimer’s disease (AD).
A New Window into Parkinson’s: Detection of Misfolded Alpha-Synuclein in Body Fluids Using the New iRS Technology
In this webinar, Prof. Klaus Gerwert shared groundbreaking research using the immuno-infrared sensor (iRS) – a technology validated in Alzheimer’s disease to directly detect αSyn misfolding in cerebrospinal fluid without seed amplification.
Sex Differences in Biofluid Biomarkers for Alzheimer’s Disease
This session offered a unique opportunity to deepen your understanding of sex differences in Alzheimer’s disease, access expert insights, and participate in a lively discussion shaping the future of biomarker research.
Precision Neurocognition: An Emerging Diagnostic Paradigm Leveraging Digital Cognitive Assessment Technology
You can now access the recording of our July Journal Club: Precision Neurocognition: An Emerging Diagnostic Paradigm Leveraging Digital Cognitive Assessment Technology.
Joint AD/PD™ and The Mosaic of Autoimmunity Webinar
This webinar brings together experts to explore cognitive decline, key pathological features like amyloid plaques and tau tangles, neuropathology, and potential autoimmune connections.
AD/PD™ Journal Club – Circulating Biomarkers and the ATN Classification: Challenges and Opportunities in Low-Resource Settings
Mark your calendars for the next AD/PD™ Journal Club! Dr. Luc Belinga will present insights from the latest publication, “Circulating Biomarkers for Alzheimer’s Disease: Unlocking the Diagnostic Potential in Low-and Middle-Income Countries, focusing on Africa”.
AD/PD™ February Journal Club!
Watch the recording of the first AD/PD™ Journal Club of 2025, where we discussed the Inflammation-Induced Dysregulation of Reelin Homeostasis Hypothesis of Alzheimer’s Disease.
AD/PD™ November Journal Club!
Watch the recording of this Journal Club, where we'll explored Classification of Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) Using Manual Motor Measures—a study that could reshape the future of neurodegenerative disease diagnosis.
AD/PD™ October Journal Club
The article explores the relationship between amyloid-β (Aβ) deposits in the brain and real-world cognitive tasks, particularly grocery shopping, in older adults who do not have cognitive impairments.
AD/PD™ October Webinar
Join us for an insightful webinar discussing the Novelties in the early detection, treatment and lifestyle interventions for Alzheimer’s disease. This session will bring together esteemed experts: Dr. Suzanne Hendrix, Dr. Galvin James, Prof. Dr. Philip Scheltens and Dr. M.L.F. Ruitenberg.
AD/PD™2024 - CME/CPD Certificate & Conference Recordings
Here's how to claim your CME/CPD Certificate after the AD/PD 2024 Conference.
COURSES
Improving Outcomes in Prodromal Alzheimer’s
Discover how a multimodal intervention—combining lifestyle changes and medical food—can improve outcomes for older adults with prodromal Alzheimer’s. This video covers key findings, participant feedback, and the potential impact of preventive strategies.
Evaluating Donanemab's Efficacy and its Role in Alzheimer's Disease Treatment
This session brought together esteemed experts Curtis P. Schrieber, MD, Giacomo Koch, MD, PhD and Miranda E. Orr, PhD to explore the implications of these findings for future research and the potential impact on patient outcomes.
α-syn pathology in the periphery: A window into early diagnosis
This session convened distinguished scholars Prof. Per Borghammer, Prof. Beomseok Jeon, Prof. Tiago Outeiro, and Prof. Erwan Bezard to delve into the intricacies and challenges surrounding the diagnosis and understanding of Parkinson's Disease (PD).
Meet the Expert interviews
At AD/PD™ 2023, we connected with leading experts like Dr. Marc Diamond, Prof. Li-Huei Tsai, and Dr. Melissa Murray. These discussions offered valuable insights into their careers and the future of Alzheimer's and Parkinson's diseases' researchers.
Entering the Era of Disease-Modifying Treatments for AD
This symposium discussed how the efficacy of anti-amyloid beta (Aβ) monoclonal antibodies (mAbs) was evaluated in clinical trials (both for therapeutic and preventive treatment of Alzheimer’s disease) versus in real-world clinical practice and explored how clinically meaningful outcomes for patients living with AD may be defined in today’s clinical practice.
Detecting Brain Amyloid Burden with PET
GE Healthcare brings its 4 module e-learning certification course on detecting brain amyloid burden with PET. In this module, learn about the evolution of MCI and AD diagnosis and the role of biomarkers. This course is open to healthcare professionals who are based in Europe.
EXCLUSIVE CONTENT
Engage, Share, and Collaborate
Are you interested in sharing your latest research findings or case studies with an attentive audience of colleagues? Would you like to lead a discussion or give an analysis of an interesting new or controversial topic? This is your chance!